维奈克拉单药治疗经B细胞受体抑制剂治疗后复发的慢性淋巴细胞白血病患者疗效:英国全国范围分析
该多中心回顾性分析纳入105例在英国国家医疗服务体系批准报销前接受维奈克拉治疗的复发/难治性慢性淋巴细胞白血病患者,中位年龄67岁,中位既往治疗线数3线。总缓解率88%(完全缓解30%),中位随访15.6个月时1年无进展生存率65.0%、1年总生存率75.1%;因疾病进展停用既往B细胞受体抑制剂者停药后进展或死亡风险为因其他原因停药者的2倍(风险比2.01,P=0.05)。
要点
- 维奈克拉在经≥1种B细胞受体抑制剂治疗的复发/难治性慢性淋巴细胞白血病中有活性且耐受良好。
- 总缓解率88%(完全缓解30%),中位随访15.6个月时1年无进展生存率65.0%、1年总生存率75.1%。
- 因疾病进展停用既往B细胞受体抑制剂者,停药后进展或死亡风险为因其他原因停药者的2倍(风险比2.01,P=0.05)。
核心结论
- 维奈克拉在经≥1种B细胞受体抑制剂治疗的复发/难治性慢性淋巴细胞白血病中有活性且耐受良好。
- 停用B细胞受体抑制剂的原因影响维奈克拉的疗效。
研究设计与样本
- 多中心回顾性分析,纳入105例在英国国家医疗服务体系批准报销前接受维奈克拉治疗的复发/难治性慢性淋巴细胞白血病患者。
- 中位年龄67岁,中位既往治疗线数3线(范围1-15线),48%存在TP53异常。
主要发现
- 在≥2线治疗患者中,60%接受过布鲁顿酪氨酸激酶抑制剂(BTKi)且未接受过磷酸肌醇3-激酶抑制剂(Pi3Ki),25%接受过Pi3Ki且未接受过BTKi,10%两者均接受过。
- 因毒性停用B细胞受体抑制剂者占44%,因疾病进展停药者占54%。
- 肿瘤溶解综合征风险低、中、高者分别占27%、25%、48%。
- 总缓解率88%(完全缓解30%);BTKi暴露患者总缓解率85%(完全缓解23%),Pi3Ki暴露患者92%(完全缓解38%),两者均暴露者80%(完全缓解20%)(P=0.59)。
- 中位随访15.6个月,1年无进展生存率65.0%,1年总生存率75.1%;减量或暂时中断未导致更差的无进展生存或免于停药生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venetoclax is a BCL2 inhibitor with activity in relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). We conducted a multi-centre retrospective analysis of 105 R/R CLL patients who received venetoclax pre-National Health Service commissioning. The median age was 67 years and median prior lines was 3 (range: 1-15). 48% had TP53 disruption. At ≥2 lines, 60% received a Bruton Tyrosine Kinase inhibitor (BTKi) and no prior phosphoinositide 3-kinase inhibitor (Pi3Ki), 25% received a Pi3Ki and no prior BTKi, and 10% received both. Patients discontinued B cell receptor inhibitor (BCRi) because of toxicity in 44% and progression in 54%. Tumour lysis syndrome risk was low, intermediate or high in 27%, 25%, and 48% respectively. Overall response was 88% (30% complete response [CR]). The overall response rate was 85% (CR 23%) in BTKi-exposed patients, 92% (CR 38%) in Pi3Ki-exposed patients and 80% (CR 20%) in both (P = 0·59). With a median follow-up of 15·6 months, 1-year progression-free survival was 65·0% and 1-year overall survival was 75·1%. Dose reduction or temporary interruption did not result in an inferior progression-free or discontinuation-free survival. Risk of progression or death after stopping a prior BCRi for progression was double compared to those stopping for other reasons (predominantly toxicity) (Hazard Ratio 2·01 P = 0·05). Venetoclax is active and well tolerated in R/R CLL post ≥1 BCRi. Reason(s) for stopping BCRi influences venetoclax outcomes.
引用
- Eyre TA, Kirkwood AA, Gohill S, et al. Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis. Br J Haematol. 2019. PMID: 30768675. doi:10.1111/bjh.15802
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。